Looks like you’re on the UK site. Choose another location to see content specific to your location
Bristol-Myers Squibb and University of Texas announce cancer alliance
Bristol-Myers Squibb has announced a new immuno-oncology-focused collaboration with the University of Texas MD Anderson Cancer Center.
The novel clinical research collaboration to evaluate multiple immunotherapies – including Opdivo, Yervoy and three early-stage clinical immuno-oncology assets – as potential treatment options for acute and chronic leukaemia as well as other haematologic malignancies.
Up to ten phase 1 and 2 clinical trials, conducted by MD Anderson, will be launched as part of the project, focused on evaluating treatments for acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome and myelofibrosis.
Immuno-oncology is a promising approach to cancer research and treatment that functions by harnessing the body's own immune system to fight the disease.
Francis Cuss, executive vice-president and chief scientific officer at Bristol-Myers Squibb, said: "Cooperation between industry and academia offers a tremendous opportunity to strengthen our scientific and clinical understanding of the role of the immune system in treating cancer."
This comes after the firm also announced a cancer-focused alliance with Novartis earlier this month.
We currently have 6 jobs available in Pharmacy industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard